Forecast 2025-2032
Published On : 05-06-2025
• As of 2023, the global Lutetium-177 (Lu-177) market was valued at approximately USD 1,564 million. With significant growth anticipated due to increasing adoption in oncology and targeted radionuclide therapy, the market is projected to reach USD 6,376.28 million by 2032. This reflects a strong compound annual growth rate (CAGR) of 16.90% over the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• The second-largest market is Europe, which has robust public healthcare systems and cutting-edge nuclear research facilities. France, the Netherlands, and Germany are among the major producers and users of Lu-177. Clinical trials and cross-border distribution are made easier by EU regulatory harmonization.Two significant European companies investing in the large-scale production of Lu-177 are Eckert & Ziegler and Isotope Technologies Munich SE. With more than 50 nuclear medicine facilities providing Lu-177 treatments as of 2024, Europe is also a leader in neuroendocrine tumor (NET) therapy.Rising cancer rates, growing nuclear medicine infrastructure, and government support are driving the fastestgrowing regional market in Asia-Pacific. To lessen their dependency on imports, nations like Australia, South Korea, China, and India are increasing their domestic production of isotopes. China's CNNC is making significant investments in facilities for the production of radiopharmaceuticals. Through public-private partnerships, Japan and Australia are increasing clinical access to theranostics based on Lu-177.
Email: help@intelmarketresearch.com +91 9169164321
Carrier-Free Lutetium-177
Carrier-Added Lutetium-177
Neuroendocrine Tumors (NETs)
Bone Metastases
Non-Hodgkin's Lymphoma
Clinical Research & Trials
